Skip to main content

Advertisement

Table 4 Surgical breast and lymph node management for the FEC and PE arms

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Surgery type FEC arm [cases (%)] PE arm [cases (%)] P value
Total 132 130  
The breast    0.456
 Breast-conserving surgery 3 (2.27) 4 (3.08)  
 Mastectomy 75 (56.82) 66 (50.77)  
 Modified radical mastectomy 54 (40.91) 60 (46.15)  
Lymph nodes    0.633
 No surgerya 0 (0.00) 1 (0.77)  
 SLNBa 1 (0.76) 2 (1.54)  
 Level I–II node dissection 28 (21.21) 21 (16.15)  
 Level I–III node dissection 86 (65.15) 89 (68.46)  
 Level I–III + supraclavicular node dissection 17 (12.88) 17 (13.08)  
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, SLNB sentinel lymph node biopsy
  2. aRequired by participants